HUP0400179A2 - 2,5-Diaril-pirazin-származékok, 2,5-diaril-piridin-származékok és 2,5-diaril-pirimidin-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények - Google Patents

2,5-Diaril-pirazin-származékok, 2,5-diaril-piridin-származékok és 2,5-diaril-pirimidin-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények

Info

Publication number
HUP0400179A2
HUP0400179A2 HU0400179A HUP0400179A HUP0400179A2 HU P0400179 A2 HUP0400179 A2 HU P0400179A2 HU 0400179 A HU0400179 A HU 0400179A HU P0400179 A HUP0400179 A HU P0400179A HU P0400179 A2 HUP0400179 A2 HU P0400179A2
Authority
HU
Hungary
Prior art keywords
group
general formula
mono
tri
atom
Prior art date
Application number
HU0400179A
Other languages
English (en)
Inventor
Dario Doller
Ping Ge
Kevin Hodgetts
Jianhua Huang
Yasuchika Yamaguchi
Original Assignee
Neurogen Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurogen Corporation filed Critical Neurogen Corporation
Publication of HUP0400179A2 publication Critical patent/HUP0400179A2/hu
Publication of HUP0400179A3 publication Critical patent/HUP0400179A3/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0459—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0463—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72—Nitrogen atoms
    • C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

A találmány (I) általános képletű 2,5-diaril-pirazin-, 2,5-diaril-piridin- és 2,5-diaril-pirimidin-származékokra vonatkozik. Az (I)általános képletben Ar1 és Ar2 jelentése - egymástól függetlenül -mono-, di- vagy triszubsztituált fenilcsoport, adott esetben mono-,di- vagy triszubsztituált 1-naftil- vagy 2-naftilcsoport vagy adottesetben mono-, di- vagy triszubsztituált, egy-háromgyűrűsheteroarilcsoport, amelynek mindegyik gyűrűje 5-7 tagú; R oxigénatomvagy nincs jelen a molekulában; Z2 jelentése nitrogénatom vagy CR2általános képletű csoport, Z3 jelentése pedig nitrogénatom vagy CR3általános képletű csoport, azzal a megkötéssel, hogy Z2 és Z3 közüllegalább az egyiknek nitrogénatomtól eltérő jelentésűnek kell lennie;R1, R2 és R3 jelentése - egymástól függetlenül - hidrogénatom,halogénatom, aminocsoport, cianocsoport, nitrocsoport, adott esetbenhelyettesített alkil-, alkenil-, alkinil-, alkoxi-, monovagy dialkil-amino-, cikloalkil-, cikloalkil-alkil-, cikloalkil-alkil-, cikloalkil-oxi-, cikloalkil-alkoxi-, alkil-tio-, alkil-szulfinil-, alkil-szulfonil-vagy mono- vagy dialkil-karboxamido-csoport, azzal amegkötéssel, hogy R1, R2 és R3 közül legalább az egyiknekhidrogénatomtól eltérő jelentésűnek kell lennie. A találmány tárgyátképezik a (I) általános képletű vegyületeket hatóanyagként tartalmazó,különböző elmebajok és idegbetegségek gyógyítására alkalmasgyógyszerkészítmények is. Ó
HU0400179A 2001-06-12 2002-05-22 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them HUP0400179A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US29748301P 2001-06-12 2001-06-12
PCT/US2002/016518 WO2002100838A1 (en) 2001-06-12 2002-05-22 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines as crf1 receptor modulators

Publications (2)

Publication Number Publication Date
HUP0400179A2 true HUP0400179A2 (hu) 2004-08-30
HUP0400179A3 HUP0400179A3 (en) 2004-10-28

Family

ID=23146501

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400179A HUP0400179A3 (en) 2001-06-12 2002-05-22 2,5-diarylpyrazines, 2,5-diarylpyridines and 2,5-diarylpyrimidines, their use and pharmaceutical compositions containing them

Country Status (16)

Country Link
US (2) US6887875B2 (hu)
EP (1) EP1399428A1 (hu)
JP (1) JP2005500286A (hu)
AP (1) AP2003002924A0 (hu)
BG (1) BG108427A (hu)
CA (1) CA2450262A1 (hu)
EC (1) ECSP034898A (hu)
HR (1) HRP20031096A2 (hu)
HU (1) HUP0400179A3 (hu)
IL (1) IL159058A0 (hu)
IS (1) IS7060A (hu)
MX (1) MXPA03011391A (hu)
PL (1) PL367476A1 (hu)
RU (1) RU2003136151A (hu)
TN (1) TNSN03133A1 (hu)
WO (1) WO2002100838A1 (hu)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1233949A2 (en) * 2000-03-16 2002-08-28 Neurogen Corporation 5-substituted arylpyrimidines
JP2005533014A (ja) * 2002-04-26 2005-11-04 ファルマシア・アンド・アップジョン・カンパニー・エルエルシー 置換ピラジン誘導体
AU2003258630A1 (en) 2002-08-19 2004-03-11 Glaxo Group Limited Pyrimidine derivatives as selective cox-2 inhibitors
GB0221443D0 (en) 2002-09-16 2002-10-23 Glaxo Group Ltd Pyridine derivates
WO2004046136A1 (en) * 2002-11-21 2004-06-03 Pharmacia & Upjohn Company Llc Pyrazine compounds as crf modulators
KR100861515B1 (ko) * 2003-11-24 2008-10-02 에프. 호프만-라 로슈 아게 피라졸릴 및 이미다졸릴 피리미딘
EP1768972A1 (de) * 2004-07-14 2007-04-04 Basf Aktiengesellschaft 2-substituierte pyrimidine, verfahren zu ihrer herstellung und ihre verwendung zur bekämpfung von schadpilzen
TW200637556A (en) * 2005-01-31 2006-11-01 Basf Ag Substituted 5-phenyl pyrimidines I in therapy
JP2009503103A (ja) * 2005-08-02 2009-01-29 レキシコン・ファーマシューティカルズ・インコーポレーテッド アリールピリジン及びその使用方法
TW200908984A (en) * 2007-08-07 2009-03-01 Piramal Life Sciences Ltd Pyridyl derivatives, their preparation and use
US7932256B2 (en) * 2008-07-31 2011-04-26 Bristol-Myers Squibb Company (S)-4-(1-cyclopropyl-2-methoxyethyl)-6-(6-(difluoromethoxy)-2,5-dimethylpyridin-3-ylamino)-5-oxo-4,5-dihydropyrazine-2-carbonitrile: a pyrazinone modulator of corticotropin-releasing factor receptor activity
EP2493871B1 (en) * 2009-10-30 2014-09-03 Domain Therapeutics Novel oxime derivatives and their use as allosteric modulators of metabotropic glutamate receptors
WO2014179786A1 (en) * 2013-05-03 2014-11-06 Inscent, Inc. Improved honeybee repellents and uses thereof
US9357781B2 (en) 2013-05-03 2016-06-07 Inscent, Inc. Honeybee repellents and uses thereof
CN103788367B (zh) * 2014-02-26 2017-01-11 中国科学院长春应用化学研究所 一种聚酯酰胺及其制备方法
JP2022074173A (ja) * 2019-03-18 2022-05-18 住友化学株式会社 ２，５－ジクロロピラジンの製造方法
CN112142716B (zh) * 2020-10-29 2021-08-31 山东新时代药业有限公司 一种5元杂芳基取代的吡嗪衍生物及其应用
CN113429354A (zh) * 2021-07-22 2021-09-24 广东嘉博制药有限公司 一种盐酸甲氧明聚合物杂质及其制备方法

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1463813A (fr) * 1964-02-26 1966-07-22 Ciba Geigy Nouvelles amino-phénylcétones et procédé pour leur préparation
US3660404A (en) * 1969-02-24 1972-05-02 Du Pont U.v.-absorbing ortho-hydroxyphenyl substituted bipyrimidyls
DE2064380C3 (de) * 1970-12-30 1981-01-22 Hoechst Ag, 6000 Frankfurt Lichtempfindliches Gemisch
JPS625970A (ja) 1985-03-15 1987-01-12 Terumo Corp ピラジン誘導体およびこれを含有する血小板凝集抑制剤
US4997942A (en) * 1988-04-25 1991-03-05 Dainippon Ink And Chemical, Inc. 2,4-disubstituted pyrazine derivatives, pyrimidine derivatives, and liquid crystal containing the same
JPH02209873A (ja) * 1989-02-08 1990-08-21 Dainippon Ink & Chem Inc 光学活性２，５―ジ置換ピリミジン誘導体
JP2770385B2 (ja) * 1989-03-16 1998-07-02 セイコーエプソン株式会社 ピリミジン誘導体
WO1995010506A1 (en) * 1993-10-12 1995-04-20 The Du Pont Merck Pharmaceutical Company 1n-alkyl-n-arylpyrimidinamines and derivatives thereof
JPH0948760A (ja) * 1995-08-03 1997-02-18 Dainippon Ink & Chem Inc ピリミジン化合物
JP4044175B2 (ja) * 1996-07-26 2008-02-06 株式会社半導体エネルギー研究所 光学活性化合物及び該化合物を含有する反強誘電性液晶組成物
US6686486B1 (en) * 1997-05-07 2004-02-03 Padma Marwah Process for effecting allylic oxidation
SE9702651D0 (sv) * 1997-07-09 1997-07-09 Astra Pharma Prod Novel compounds
AU742641B2 (en) * 1998-01-28 2002-01-10 Shionogi & Co., Ltd. Novel tricyclic compound
CO5210940A1 (es) * 1999-05-04 2002-10-30 Novartis Ag Compuestos plaguicidas derivados de pirimidina y composiciones que los contienen
SK11542002A3 (sk) * 2000-02-16 2003-03-04 Neurogen Corporation Substituované arylpyrazíny

Also Published As

Publication number Publication date
AP2003002924A0 (en) 2003-12-31
PL367476A1 (en) 2005-02-21
EP1399428A1 (en) 2004-03-24
US20030119844A1 (en) 2003-06-26
HUP0400179A3 (en) 2004-10-28
ECSP034898A (es) 2004-01-28
WO2002100838A1 (en) 2002-12-19
HRP20031096A2 (en) 2005-08-31
US20050176721A1 (en) 2005-08-11
JP2005500286A (ja) 2005-01-06
BG108427A (en) 2005-01-31
RU2003136151A (ru) 2005-05-20
TNSN03133A1 (en) 2005-12-23
IS7060A (is) 2003-11-28
IL159058A0 (en) 2004-05-12
CA2450262A1 (en) 2002-12-19
MXPA03011391A (es) 2004-07-01
US6887875B2 (en) 2005-05-03

Similar Documents

Publication Publication Date Title
HUP0400179A2 (hu) 2,5-Diaril-pirazin-származékok, 2,5-diaril-piridin-származékok és 2,5-diaril-pirimidin-származékok, alkalmazásuk és ezeket tartalmazó gyógyszerkészítmények
HUP0400766A2 (hu) Vírusellenes hatású imidazopiridin- és imidazopirimidin-származékok, ezeket tartalmazó készítmények és előállításuk
HUP0402458A2 (hu) Fokozott hatékonyságú kemokin receptor kötő heterociklusos vegyületek
MA29213B1 (fr) Quinolones a substitution macrolones - amino
MY146669A (en) Pyrazole derivatives for treating hiv
PT1404347E (pt) Nucleosidos 4'-substituidos para o tratamento de doencas mediadas pelo virus da hepatite c
HUP0102521A2 (hu) Sztilbénszármazékot és platina koordinációs vegyületet tartalmazó daganatellenes szer
MXPA03005464A (es) Agentes antivirales.
MXPA05013059A (es) Derivados de 2-amino-piridina como agonistas del adrenoceptor beta-2.
HK1057752A1 (en) N-phenyl-2-pyrimidine-amine derivatives
MY140488A (en) Substituted oxazolidinones and their use in the field of blood coagulation
BRPI0409227B8 (pt) "composto, composição farmacêutica, uso de um composto e processo para a preparação de um composto de fórmula (i)"
EP1689713A4 (en) BENZYLETHER AND BETA-SECRETASE BENZYLAMINO INHIBITORS FOR TREATING ALZHEIMER'S DISEASE
NO20035211D0 (no) Faste farmasöytiske formuleringer omfattende modafinil
HUP0400316A2 (hu) CRF1 modulátor hatású 5-szubsztituált-2-arilpiridin származékok és ezeket tartalmazó gyógyszerkészítmények
IL184116A0 (en) Use of thiazolidinone derivatives as antiangiogenic agents
TR200402529T4 (tr) Yeni Fenalliloksi fenil türevleri.
TW200505865A (en) Compounds useful for the treatment of diseases
TNSN08537A1 (fr) Precurseurs de medicaments du type peneme
BR0001201A (pt) Composto ( poli ) tia-alcinóicos, composição cosmética, utilização de uma composição cosmética, utilização de um composto e composição farmacêutica
AU2003263498A1 (en) Pyrazole derivatives
EA200600316A1 (ru) ПРОИЗВОДНЫЕ 3-НИТРОПИРАЗОЛО[1,5-a]ПИРИМИДИНОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ И ИСПОЛЬЗУЕМЫЕ В НЕМ ПРОМЕЖУТОЧНЫЕ СОЕДИНЕНИЯ (ВАРИАНТЫ), ЛЕКАРСТВЕННОЕ СРЕДСТВО (ВАРИАНТЫ) И СПОСОБ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ ЗАБОЛЕВАНИЙ, СВЯЗАННЫХ С МОДУЛЯЦИЕЙ РЕЦЕПТОРА ГАМК(ВАРИАНТЫ)
HUP0402124A2 (hu) Pszichofarmakológiában alkalmazható pirazolszármazékok, eljárás az előállításukra és ezeket tartalmazó gyógyszerkészítmények
ATE274515T1 (de) Pyrazolopyridinderivate
MXPA04005151A (es) Compuestos terapeuticos.